$AKTS
Aktis Oncology, Inc. Common stock
XNAS•Health Care•Pharmaceutical Preparations
$21.88
▼-4.29%-$0.980
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAktis Oncology, Inc. Common stock
XNAS•Health Care•Pharmaceutical Preparations
Why is AKTS down today? It is at $21.88 (-4.29%), and our scanner flagged it 53 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment AKTS spikes, and full due diligence on AKTS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $AKTS 53 times in the last 30 days. Create a free account to track $AKTS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on AKTS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for AKTS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Across every filing on file, supply equal to 204.2% of the tradeable float is in play - 204.2% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
At-the-market (ATM) program — sells new shares into the market gradually over time · About $700.0M in size
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Herrmann Ken Director | Sold (automatic/other) | -5K | n/a | n/a | $119K at $24.56 | Jul 20, 26 |
Herrmann Ken Director | Other | 5K | n/a | 5K | $388 at $0.080 | Jul 20, 26 |
Herrmann Ken Director | Sold (automatic/other) | -3K | n/a | n/a | $77K at $25.21 | Jul 17, 26 |
Herrmann Ken Director | Other | 3K | n/a | 3K | $245 at $0.080 | Jul 17, 26 |
Czibere Akos Officer | Sold (automatic/other) | -50K 0.09% of company | n/a | n/a | $1.4M at $27.13 | Jul 8, 26 |
Czibere Akos Officer | Other | 50K 0.09% of company | n/a | 50K | $248K at $4.95 | Jul 8, 26 |
Ron-Bigger Shulamit Officer | Sold (automatic/other) | -50K 0.09% of company | n/a | n/a | $1.4M at $27.13 | Jul 8, 26 |
Ron-Bigger Shulamit Officer | Other | 50K 0.09% of company | n/a | 50K | $183K at $3.66 | Jul 8, 26 |
Segal Lloyd Mitchell Director | Acquired (grant/award) | +20K 0.04% of company | n/a | 20K | n/a | Jan 12, 26 |
Kim Helen Susan Director | Acquired (grant/award) | +4.99M 9.3% of company | n/a | 4.86M | n/a | Jan 12, 26 |
Kim Helen Susan Director | Bought (open market) | +835K 1.6% of company | added 17% | 5.83M | $15.0M at $18.00 | Jan 12, 26 |
Vida Ventures Ii, Llc Beneficial Owner (10%) | Acquired (grant/award) | +4.99M 9.3% of company | n/a | 4.86M | n/a | Jan 12, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on AKTS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for AKTS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
AKTS last traded at $21.88, down 4.29% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Aktis Oncology, Inc. Common stock (AKTS) is next expected to report earnings on Thursday, November 12, 2026, about 53 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The AKTS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged AKTS 53 times in the last 30 days.
AKTS (Aktis Oncology, Inc. Common stock) trades on XNAS, with a market cap of about $1.17B in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge AKTS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$AKTS discussion
Sign in to ask a question or join the discussion.